# Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

> **NCT04641143** · PHASE3 · COMPLETED · sponsor: **Biohaven Pharmaceuticals, Inc.** · enrollment: 456 (actual)

## Conditions studied

- Obsessive-Compulsive Disorder

## Interventions

- **DRUG:** Troriluzole
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04641143
- **Lead sponsor:** Biohaven Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-22
- **Primary completion:** 2025-10-27
- **Final completion:** 2025-10-27
- **Target enrollment:** 456 (ACTUAL)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04641143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04641143, "Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04641143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*